NRIX

Nurix Therapeutics, Inc.

• Dow Jones·1d ago

  Nurix Therapeutics Is Maintained at Overweight by Morgan Stanley

• Benzinga·1d ago

  Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

• TipRanks·1d ago

  Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Nurix Therapeutics (NRIX) and Johnson & Johnson (JNJ)

• Reuters·1d ago

  U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit

• Dow Jones·07/22 18:54

  Nurix Therapeutics Is Maintained at Buy by UBS

• Benzinga·07/22 18:45

  UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

• Reuters·07/22 14:12

  NURIX THERAPEUTICS INC <NRIX.O>: UBS RAISES TARGET PRICE TO $31 FROM $23

• TipRanks·07/22 11:40

  Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Celldex (CLDX) and Nurix Therapeutics (NRIX)

• TipRanks·07/22 11:31

  Nurix Therapeutics price target raised to $31 from $23 at UBS

• Reuters·07/22 08:07

  U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI

• NASDAQ·07/22 05:06

  Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront

• Benzinga·07/21 20:07

  Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%

• Benzinga·07/21 20:06

  Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone Payments

• Benzinga·07/21 20:03

  Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period

• PUBT·07/21 20:01

  Nurix Therapeutics, Roche partner to co-develop BTK degrader bexobrutideg in deal worth up to $2.3 billion